Pharmacokinetic drug-drug interaction between olaparib and apixaban: a case report

Cancer Chemother Pharmacol. 2024 May;93(5):519-521. doi: 10.1007/s00280-023-04606-8. Epub 2023 Nov 3.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Drug Interactions*
  • Factor Xa Inhibitors / adverse effects
  • Factor Xa Inhibitors / pharmacokinetics
  • Humans
  • Phthalazines* / adverse effects
  • Phthalazines* / pharmacokinetics
  • Piperazines* / administration & dosage
  • Piperazines* / adverse effects
  • Piperazines* / pharmacokinetics
  • Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacokinetics
  • Pyrazoles* / adverse effects
  • Pyrazoles* / pharmacokinetics
  • Pyridones* / administration & dosage
  • Pyridones* / adverse effects
  • Pyridones* / pharmacokinetics

Substances

  • apixaban
  • Factor Xa Inhibitors
  • olaparib
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Pyrazoles
  • Pyridones